FDA Approves Immunocore’s Kimmtrak for Rare Eye Cancer
Immunocore’s Kimmtrak (tebentafusp-tebn) has won FDA approval for treating inoperable or metastatic uveal melanoma, a rare adult eye cancer with poor prognosis.
Source: Drug Industry Daily
Immunocore’s Kimmtrak (tebentafusp-tebn) has won FDA approval for treating inoperable or metastatic uveal melanoma, a rare adult eye cancer with poor prognosis.
Source: Drug Industry Daily